CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Hold” by Analysts
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have received an average rating of “Hold” from the twenty-one research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have issued a buy recommendation on […]
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have received an average rating of “Hold” from the twenty-one research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have issued a buy recommendation on […]
